Data + PerspectivesExploring the Role of Novel Agents

and Emerging Strategies in the Management of Acute Myeloid Leukemia

Friday, December 6, 20197:30 AM – 9:30 AMOrlando, Florida

Faculty

ModeratorNeil Love, MD

Mark Levis, MD, PhDDaniel A Pollyea, MD, MS

Richard M Stone, MDAndrew H Wei, MBBS, PhD

Disclosures for Moderator Neil Love, MD

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharmaInc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, SirtexMedical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

Agenda

Module 1 – Dr Pollyea: Evolving Paradigms in Up-Front Treatment for Older Patients or Those Ineligible for Intensive Chemotherapy

Module 2 – Dr Stone: Assessment, Incidence and Clinical Significance of FLT3 Mutations in AML

Module 3 – Dr Levis: Long-Term Treatment for Patients with AML with IDH Mutations

Module 4 – Prof Wei: Other Novel Agents and Promising Strategies Under Evaluation for Patients with AML

The patients I saw today…

82 M Chronic myeloid leukemia - Newly diagnosed, Sokalintermediate risk, I recommended dasatinib

42 F Breast Cancer - Stage III TNBC s/p adjuvant DD AC-T

89 M Acute Myeloid Leukemia - Venetoclax/azacitidine

38 F Colorectal Cancer - Metastatic colon cancer on FOLFOX/bevacizumab

76 M Hepatocellular carcinoma – Nivolumab

71 F Diffuse Large B Cell Lymphoma - Completed R-CHOP

84 M Multiple myeloma - Bortezomib/Dex

59 M Multiple myeloma or other plasma cell dyscrasias –Maintenance Carfilzomib/Dex

62 M Multiple myeloma - Relapsed/Refractory-Carfilzomib/Cyclophosphamide/Dex

72 F Breast Cancer – Anastrozole

54 F Breast Cancer – Tamoxifen

35 M Benign Hematology - Enoxaparin for DVT

32 F Benign Hematology - DSVT on warfarin

40 F Benign Hematology - Iron def anemia on oral iron

42 F T-Cell Lymphoma - T-Cell LGL on weekly Methotrexate

68 M Diffuse Large B Cell Lymphoma - Primary CNS lymphoma s/p HD- Methotrexate/Rituximab

57 F Melanoma - Ipi/Nivo

62 M Renal Cell Carcinoma - Ipi/Nivo

62 M Lung Cancer - Consolidative Durvalumab after chemoRT

92 M Prostate cancer - Enzalutamide/Leuprolide/Denosumab

Exploring Current Management Paradigms for Patients with Acute Myeloid Leukemia

Not Eligible for Intensive Therapy

FacultyCourtney D DiNardo, MD, MSCE

Keith W Pratz, MDRichard M Stone, MD

ModeratorNeil Love, MD

Friday, October 25, 2019, 1:15 PM – 3:45 PMOrlando, Florida

N = 26 investigators

Survey Participants

Amy DeZern, MD, MHSCourtney D DiNardo, MD, MSCEJames Dugan, MDHarry P Erba, MD, PhDAmir Fathi, MDSteven D Gore, MDJonathan A Gutman, MDCatherine Lai, MDThomas LeBlanc, MDMark Levis, MD, PhDGabriel Mannis, MDRebecca Olin, MD, MSCEAlexander Perl, MD, MS

Daniel A Pollyea, MD, MSKeith W Pratz, MDFarhad Ravandi, MDGary J Schiller, MDEytan M Stein, MDWendy Stock, MDRichard M Stone, MDKendra Sweet, MD, MSGeoffrey L Uy, MDRoland Walter, MD, PhD, MSEunice Wang, MDAndrew H Wei, MBBS, PhDJoshua F Zeidner, MD

N = 25

What initial treatment would you recommend for a 65-year-old man with AML with a PS of 1 and pancytopenia, 35% marrow myeloblasts, a complex karyotype and a TP53 mutation?

12Azacitidine + venetoclax

CPX-351 6

Decitabine + venetoclax 6

1FLAG-Ida